Drug Sponsors

Bioasis establishes U.S. presence with office in Connecticut

Wednesday, October 11, 2017

Bioasis Technologies, a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, announced the establishment of its U.S. office in Guilford, Conn. Additionally, the company has launched its new corporate website, bioasis.us.

[Read More]

Ultragenyx to acquire Dimension Therapeutics

Wednesday, October 4, 2017

Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Dimension Therapeutics have entered into a definitive merger agreement under which Ultragenyx will acquire all of the outstanding shares of common stock of Dimension for $6.00 per share, or approximately $151 million in cash, based on currently outstanding shares. The transaction is structured as a tender offer and will be funded through Ultragenyx’s existing cash resources.

[Read More]

Catalent to acquire Cook Pharmica for $950M

Tuesday, September 19, 2017

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services. The purchase price is $950 million, with $750 million to be paid at closing and the balance to be paid in equal installments, without interest, on each of the next four anniversaries of the closing. The acquisition will strengthen Catalent’s position as a leader in the rapidly growing area of biologics development and analytical services, manufacturing, and finished product supply.

[Read More]

TransCelerate BioPharma adds Novartis

Monday, September 18, 2017

TransCelerate BioPharma announces the addition of Novartis to the biopharmaceutical nonprofit organization, growing the consortium to 19 biopharmaceutical companies. In addition, TransCelerate membership have elected Elliott Levy, M.D., Senior Vice President, Global Development at Amgen as the new Chair of the Board of the Directors and David Nicholson, Ph.D., Executive Vice President, and Chief R&D Officer at Allergan, will assume the Vice Chair role.

[Read More]

ProQR spins out Amylon Therapeutics for CNS therapeutics

Wednesday, September 13, 2017

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders.

[Read More]

Alexion restructures, cuts workforce 20%

Wednesday, September 13, 2017

Alexion Pharmaceuticals announced an operational plan to re-align the global organization with its refocused corporate strategy. The plan is expected to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019. The restructuring will reduce the company’s global workforce by approximately 20%. The resulting savings will allow Alexion to prioritize investments to advance growth opportunities, optimize capabilities across the organization, and position Alexion to deliver on its financial ambitions, including growing GAAP operating margin to 37% and non-GAAP operating margin to 50% in 2019.

[Read More]

Inotek, Rocket announce merger agreement

Wednesday, September 13, 2017

Inotek Pharmaceuticals has entered into a definitive merger agreement with Rocket Pharmaceuticals, a U.S.-based gene therapy company. Subject to shareholder approval, the combined company will retain the name Rocket Pharmaceuticals and will be headquartered in New York City. The combined company will focus on developing and advancing its pipeline of gene therapies based on lentiviral virus (LVV) and adeno-associated virus (AAV) gene therapy platforms, with a focus on treating devastating rare diseases.

[Read More]